Terms: = Sarcomas AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
143 results:
1. Screening for Synergistic Reagents With Pazopanib Against Osteosarcoma Using a Compound Library.
Yada Y; Asanuma K; Kakimto T; Okuno K; Okamoto T; Iino T; Nakamura T; Sudo A
Anticancer Res; 2024 Mar; 44(3):1071-1078. PubMed ID: 38423639
[TBL] [Abstract] [Full Text] [Related]
2. A study protocol for an open-label, single-arm, single-center phase I clinical study on tolerability, safety, and efficacy of dalpiciclib combined with apatinib in the treatment of patients with advanced or metastatic sarcoma.
Huang H; Zhang H; Cao B
Thorac Cancer; 2024 Feb; 15(5):427-433. PubMed ID: 38211967
[TBL] [Abstract] [Full Text] [Related]
3. A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas.
Zhou Y; Li M; Zhang B; Yang C; Wang Y; Zheng S; Tang L; Zhou C; Qian G; Huang Y; Yu W; Li H; Wang Y; He A; Shen Z; Zhang J; Li X; Yang Q; Hu H; Yao Y
BMC Med; 2023 Nov; 21(1):470. PubMed ID: 38031088
[TBL] [Abstract] [Full Text] [Related]
4. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
5. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
7. Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study.
Phadnis S; Wang X; Daw NC; Herzog CE; Subbiah IM; Zaky W; Gouda MA; Morani AC; Amini B; Harrison DJ; Piha-Paul SA; Meric-Bernstam F; Gorlick R; Schwartz CL; Subbiah V
ESMO Open; 2023 Dec; 8(6):101609. PubMed ID: 37879233
[TBL] [Abstract] [Full Text] [Related]
8. Kaposi's sarcoma-associated herpesvirus viral protein kinase augments cell survival.
Wu XJ; Zhang Z; Wong JP; Rivera-Soto R; White MC; Rai AA; Damania B
Cell Death Dis; 2023 Oct; 14(10):688. PubMed ID: 37852997
[TBL] [Abstract] [Full Text] [Related]
9. In vivo self-assembly and delivery of vegfr2 siRNA-encapsulated small extracellular vesicles for lung metastatic osteosarcoma therapy.
Yu L; Fan G; Wang Q; Zhu Y; Zhu H; Chang J; Wang Z; Zhan S; Hua X; She D; Huang J; Wang Y; Zhao J; Zhang CY; Chen X; Zhou G
Cell Death Dis; 2023 Sep; 14(9):626. PubMed ID: 37739958
[TBL] [Abstract] [Full Text] [Related]
10. E7050 Suppresses the Growth of Multidrug-Resistant Human Uterine Sarcoma by Inhibiting Angiogenesis via Targeting of vegfr2-Mediated Signaling Pathways.
Huang TT; Chen CM; Lin SS; Lan YW; Cheng HC; Choo KB; Wang CC; Huang TH; Chong KY
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298555
[TBL] [Abstract] [Full Text] [Related]
11. Primary and secondary angiosarcomas of the liver: a multi-institutional study of 32 cases.
Liao X; Lai J; Lin J; Zhang D
Hum Pathol; 2023 Jul; 137():10-17. PubMed ID: 37054784
[TBL] [Abstract] [Full Text] [Related]
12. Efficacy and safety of fruquintinib as third- or further-line therapy for patients with advanced bone and soft tissue sarcoma: a multicenter retrospective study.
Ding X; Liu Y; Zhang Y; Liang J; Li Q; Hu H; Zhou Y
Anticancer Drugs; 2023 Aug; 34(7):877-882. PubMed ID: 36539356
[TBL] [Abstract] [Full Text] [Related]
13. Receptor Tyrosine Kinase Inhibitors for the treatment of Recurrent and Unresectable Bone sarcomas.
Albarrán V; Villamayor ML; Chamorro J; Rosero DI; Pozas J; San Román M; Calvo JC; Pérez de Aguado P; Moreno J; Guerrero P; González C; García de Quevedo C; Álvarez-Ballesteros P; Vaz MÁ
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430263
[TBL] [Abstract] [Full Text] [Related]
14. Multi-omics analysis identifies osteosarcoma subtypes with distinct prognosis indicating stratified treatment.
Jiang Y; Wang J; Sun M; Zuo D; Wang H; Shen J; Jiang W; Mu H; Ma X; Yin F; Lin J; Wang C; Yu S; Jiang L; Lv G; Liu F; Xue L; Tian K; Wang G; Zhou Z; Lv Y; Wang Z; Zhang T; Xu J; Yang L; Zhao K; Sun W; Tang Y; Cai Z; Wang S; Hua Y
Nat Commun; 2022 Nov; 13(1):7207. PubMed ID: 36418292
[TBL] [Abstract] [Full Text] [Related]
15. Case Report: Anlotinib combined with PD-1 inhibitor and sequential GA regimen or FOLFIRINOX Chemotherapy in treatment of KRAS G12V mutated pancreatic ductal adenocarcinoma with liver metastasis: A case and literature review.
Wang Y; Wang B; Xiang L; Deng J; Xu B; He P; Pu W; Wang H; Fan Y; Chen H
Front Immunol; 2022; 13():1016647. PubMed ID: 36311715
[TBL] [Abstract] [Full Text] [Related]
16. Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Gales L; Forsea L; Mitrea D; Stefanica I; Stanculescu I; Mitrica R; Georgescu M; Trifanescu O; Anghel R; Serbanescu L
Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143915
[TBL] [Abstract] [Full Text] [Related]
17. OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma.
Thiebaud JA; Ravi V; Litwin S; Schuetze SM; Movva S; Agulnik M; Kraft AS; Tetzlaff ED; Somaiah N; von Mehren M
Cancer; 2022 Oct; 128(19):3516-3522. PubMed ID: 35942596
[TBL] [Abstract] [Full Text] [Related]
18. Gene expression-based prediction of pazopanib efficacy in sarcoma.
Heilig CE; Laßmann A; Mughal SS; Mock A; Pirmann S; Teleanu V; Renner M; Andresen C; Köhler BC; Aybey B; Bauer S; Siveke JT; Hamacher R; Folprecht G; Richter S; Schröck E; Brandts CH; Ahrens M; Hohenberger P; Egerer G; Kindler T; Boerries M; Illert AL; von Bubnoff N; Apostolidis L; Jost PJ; Westphalen CB; Weichert W; Keilholz U; Klauschen F; Beck K; Winter U; Richter D; Möhrmann L; Bitzer M; Schulze-Osthoff K; Brors B; Mechtersheimer G; Kreutzfeldt S; Heining C; Lipka DB; Stenzinger A; Schlenk RF; Horak P; Glimm H; Hübschmann D; Fröhling S
Eur J Cancer; 2022 Sep; 172():107-118. PubMed ID: 35763870
[TBL] [Abstract] [Full Text] [Related]
19. Systemic Therapy in Patients With Metastatic Xp11.2 Translocation Renal Cell Carcinoma.
Yan X; Zhou L; Li S; Wu X; Cui C; Chi Z; Si L; Kong Y; Tang B; Li C; Mao L; Wang X; Lian B; Bai X; Dai J; Guo J; Sheng X
Clin Genitourin Cancer; 2022 Aug; 20(4):354-362. PubMed ID: 35387755
[TBL] [Abstract] [Full Text] [Related]
20. Identification of Gαi3 as a promising target for osteosarcoma treatment.
Bian ZJ; Shan HJ; Zhu YR; Shi C; Chen MB; Huang YM; Wang XD; Zhou XZ; Cao C
Int J Biol Sci; 2022; 18(4):1508-1520. PubMed ID: 35280670
[TBL] [Abstract] [Full Text] [Related]
[Next]
